FEDERAL TRADE COMMISSION v. ENDO PHARMACEUTICALS INC. et al

  1. March 24, 2022

    Endo Wins Dismissal Of FTC's Suit Over Impax Opioid Deal

    Endo Pharmaceuticals on Thursday secured a D.C. federal court's dismissal of the Federal Trade Commission's antitrust suit accusing it of entering a second "pay-for-delay" agreement with Impax Laboratories to stave off competition to Endo's Opana ER painkiller.

  2. June 11, 2021

    Endo Can't Shake FTC Pay-For-Delay Suit, Judge Told

    The Federal Trade Commission fought a dismissal bid Friday in an antitrust suit related to an alleged 2017 "pay-for-delay" agreement over Endo Pharmaceuticals' Opana ER painkiller, saying the drugmaker couldn't have made such an agreement because its competitor had already had a broad patent license for similar products for years.

  3. April 27, 2021

    Endo Says FTC Is Overreacting To Latest Impax Opioid Deal

    Endo Pharmaceuticals is pushing for the dismissal of a Federal Trade Commission antitrust suit alleging it entered a second "pay-for-delay" agreement with Impax Laboratories over Endo's Opana ER painkiller, arguing the Patent Act and antitrust laws allow it to license its opioids to whomever it wants while excluding the competition.

  4. January 25, 2021

    FTC Says Endo, Impax Cut 2nd Opana ER Pay-For-Delay Deal

    The Federal Trade Commission filed a new antitrust complaint Monday accusing Endo Pharmaceuticals and Impax Laboratories of striking a second deal to stave off competition to the Opana ER opioid pain medication even as an earlier FTC enforcement action over the same drug was moving forward.